Pharmaceutical compositions of anisomelic acid and the use thereof

A technology of Fangfeng oxalic acid and its composition, applied in the field of Fangfeng oxalic acid and its composition in antiviral cancer treatment, and the pharmaceutical composition of Fangfeng oxalic acid, which can solve problems such as genome instability

Active Publication Date: 2015-08-26
ANISON THERAPEUTICS OY
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As a result, the cell cycle checkpoints of G1 / S and G2 / M are lost, and cells are prone to genomic instability, which may lead to tumor development

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions of anisomelic acid and the use thereof
  • Pharmaceutical compositions of anisomelic acid and the use thereof
  • Pharmaceutical compositions of anisomelic acid and the use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0066] Experimental results presented below show that AA depletes viral oncoproteins E6 / E7 and inhibitor of apoptosis protein 2 (cIAP2), and thus, involves apoptosis in SiHa HPV16 positive cervical cancer cells. AA also activates the p53-p21 pathway leading to G2 / M cell cycle arrest.

[0067] The results showed that AA emulsion was more effective in inducing apoptosis at an earlier time point than AA alone. AA emulsions also effectively inhibited the growth of tumors in the CAM model.

[0068] Mammalian models are often used for preclinical evaluation of new drug delivery systems (DDS). However, valid mammalian models are expensive, time-consuming, and not easy to establish and evaluate. Furthermore, they often involve administrative burdens, both ethical and legal. Therefore, we used chorioallantoic membrane (CAM) as a surrogate for evaluating mammalian models of DDS. Study the characteristics of the CAM, embryonic anatomy, and blood to assess drug carrier properties such...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A pharmaceutical composition for anti-viral cancer treatment in mammals, comprising a therapeutically effective amount of Anisomelic acid or salts thereof. The pharmaceutical composition may comprise Anisomelic acid or salt thereof in an oil-in-water emulsion, for example in an isotropic mixture of at least one oil and at least one surfactant or, alternatively, in a hydrophilic solvent and a co-solvents or surfactant or a combination thereof. A method of treating or preventing of cancer in a mammal, wherein the p53 pathway is deregulated by viral oncoproteins, is also provided.

Description

technical field [0001] The present invention relates to a new application of a compound Anisomelic acid (AA), which is isolated from Anisomeles malabarica. In particular, the present invention relates to the pharmaceutical composition of parsnip oxalic acid. The invention also discloses the use of the parsnip oxalic acid and its composition in antiviral cancer treatment. Background technique [0002] Cervical cancer is the second most common malignancy affecting women worldwide, with approximately 500,000 new cases diagnosed each year, and 280,000 deaths. Although surgery and chemo-radiation therapy cure 80-95% of women with early stage cancer and 60% and 60% of locally advanced cancer, disease recurrence and metastasis remain the leading causes of cancer death. Current options for cytotoxic treatment of advanced and metastatic cancers show mediocre results, with response rates of maximal 30% and overall survival numbers of less than 10 months. With the limited success of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P35/00A61P31/20
CPCA61K31/365A61K9/4825A61K9/107A61K9/0014A61P31/12A61P31/20A61P35/00
Inventor 约翰·埃里克森普里赛·保罗伊米莉亚·佩乌胡M·A·阿卡巴尔沙
Owner ANISON THERAPEUTICS OY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap